Brokerages Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) Target Price at $62.78
Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) have been given an average rating of “Moderate Buy” by the ten analysts that are presently covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The […]
Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) have been given an average rating of “Moderate Buy” by the ten analysts that are presently covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The […]
